These contrasts motivate a two-dimensional biomarker strategy: (i) a tumor-cell IP score (e.g., PSMB8/9/10 protein by immunohistochemistry (IHC) or RNA composite), and (ii) an immune-context score (cytotoxic infiltration, IFN-γ signatures, myeloid polarization, acidity/hypoxia proxies). This evidence concerns the gene IFNG and neoplasm.